YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Genmab A/S Company Announcement COPENHAGEN, Denmark; October 7, 2026 – Genmab A/S (Nasdaq: GMAB) Today, Genmab A/S held an Extraordinary General Meeting. At the Extraordinary General Meeting the proposal from the Board of Directors on remu…
Genmab stock: what the latest trial results mean for investors Genmab (CPSE:GMAB) is suddenly back on many watchlists after two fresh clinical readouts in oncology, including a Phase 3 win for epcoritamab in newly diagnosed diffuse large B…
AbbVie (NYSE:ABBV) and Genmab reported positive topline Phase 3 EPCORE DLBCL-2 data for epcoritamab plus R-CHOP in newly diagnosed DLBCL. The combination reduced the risk of disease progression or death by 51% versus standard R-CHOP alone,…
AbbVie ABBV, along with Genmab GMAB, announced positive top-line data from the phase III EPCORE DLBCL-2 study, which evaluated epcoritamab in combination with standard-of-care rituximab, cyclophosphamide, doxorubicin hydrochloride, vincris…
Investing.com -- Shares of Genmab surged more than 8% in early trading Tuesday after the Danish biotech and AbbVie said their combination treatment for newly diagnosed patients with a type of lymphoma reduced the risk of disease progressio…
Genmab A/S Sponsored ADR (GMAB) shares rallied 10.7% in the last trading session to close at $38.48. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to th…
Investing.com - European equities drifted in a narrow range on Tuesday morning, attempting to build a floor after a violent global bond rout and French fiscal shocks severely disrupted the opening sessions of the fourth quarter. Before you…
The addition of Genmab's Epkinly to a standard cocktail of drugs helped lymphoma patients live longer before worsening. Genmab stock rocketed. Continue Reading
Investing.com -- Genmab A/S (NASDAQ:GMAB) shares rose 11% Monday afternoon following the announcement of positive topline results from a Phase 3 trial of epcoritamab in combination with R-CHOP for newly diagnosed diffuse large B-cell lymph…
EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival (PFS) in frontline diagnosed diffuse large B…
EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival (PFS) in frontline diagnosed diffuse large B…
Genmab A/S Company Announcement COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; October 5, 2026 EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically mea…
Investing.com -- Shares of Genmab jumped more than 4% Monday after the Danish biotech reported that its experimental ovarian cancer drug, Rina-S, produced durable and clinically meaningful responses in patients with platinum-resistant ovar…
Treatment with Rina-S® 120 mg/m² every three weeks demonstrated a clinically meaningful objective response rate (ORR) and durable median duration of response (mDOR) in patients with platinum-resistant ovarian cancer (PROC) Antitumor activi…
Genmab A/S Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; October 2, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Darwin Global Man…
Genmab A/S Company Announcement COPENHAGEN, Denmark; September 24, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 13,794 restricted stock units and 13,331 warrants to employees of the Company…
The consensus analyst Price Target fair value for Genmab has been adjusted to DKK 2,303.24 from DKK 2,453.79, pointing to a slightly lower central target level for the stock. Analysts link this change to a balance of confidence in Genmab's…
Genmab A/S Company Announcement COPENHAGEN, Denmark; September 8, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 28,011 shares as a consequence of the exercise of employee warrants. The increase is effected without any…
During these busy times, it pays to stay on top of the latest profit opportunities. And today's blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company's fu…
Genmab A/S Company Announcement Genmab A/S to hold an Extraordinary General Meeting on Wednesday, October 7, 2026 COPENHAGEN, Denmark; September 8, 2026 – Genmab A/S (Nasdaq: GMAB) convenes an Extraordinary General Meeting to be held on We…
Genmab A/S (NASDAQ:GMAB) boosted its full-year 2026 revenue guidance to a range of $4.325 billion to $4.525 billion, up from its previous outlook of $4.065 billion to $4.395 billion. The upward revision underscores the strong commercial mo…
Genmab A/S Media Release COPENHAGEN, Denmark; August 25, 2026 Genmab A/S(Nasdaq:GMAB)announced today that members of its Executive Committeewill participate in fireside chats at the following investorconferences in September 2026: Wells Fa…
During these busy times, it pays to stay on top of the latest profit opportunities. And today's blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company's fu…
On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20). The Phase 3 EPCORE DLBCL-1 study evalu…
Pre-Market Stock Futures: Futures are trading modestly higher as we have arrived at the day everyone on Wall Street has circled on their calendars. The July consumer price index will be released at 8:30 AM EDT, and the producer price index…
Genmab A/S Company Announcement COPENHAGEN, Denmark; August 11, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 24,592 shares as a consequence of the exercise of employee warrants. The increase is effected without any p…
This article first appeared on GuruFocus. Genmab (NASDAQ:GMAB), a biotechnology company focused on antibody medicines, delivered another quarter that reminded investors why royalty businesses can be so powerful. First-half revenue climbed…
Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 12:00 p.m. ET CALL PARTICIPANTS Chief Executive Officer - Jan van de WinkelChief Financial Officer - Anthony PaganoChief Commercial Officer - Brad BaileyChief Medical Officer -…
This article first appeared on GuruFocus. Total Revenue Growth: Increased 25% year-over-year in the first half of 2026. Proprietary Portfolio Sales: Totaled DKK396 million, a 37% increase compared to the same period last year. EPKINLY Sale…
Investing.com -- Genmab shares jumped over 8% on Friday, a day after the Danish biotech beat second-quarter expectations and raised its 2026 sales and profit outlook, while confirming a critical bispecific-antibody drug trial readout due i…
Genmab A/S August 6, 2026 Copenhagen, Denmark; Interim Report for the Six Months Ended June 30, 2026 Highlights Genmab announced positive Phase 3 results for epcoritamab plus lenalidomide in patients with relapsed/refractory diffuse large…
AbbVie ABBV reported second-quarter 2026 adjusted EPS of $3.65, which beat the Zacks Consensus Estimate of $3.64. The reported figure also exceeded the company's guidance of $3.57-$3.61 per share, issued earlier in July 2026. Earnings rose…
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Genmab and AbbVie (ABBV) recently clarified that the U.S. portion of the Phase 3 EPCORE DLBCL-1 t…
(RTTNews) - Genmab A/S (GMAB) and AbbVie Inc. (ABBV) on Thursday announced that the Phase 3 EPCORE DLBCL-1 trial evaluating Epcoritamab in adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) failed to meet its U.…
Genmab A/S Media Release COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; July 23, 2026 Genmab and AbbVie clarify overall survival (OS) was the sole U.S. primary endpoint in the Phase 3 EPCORE® DLBCL-1 trial and was not met Genmab A/S(Nasdaq:…
Genmab and AbbVie clarify overall survival (OS) was the sole U.S. primary endpoint in the Phase 3 EPCORE® DLBCL-1 trial and was not met COPENHAGEN, Denmark & NORTH CHICAGO, Ill., July 23, 2026--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) an…